Tscan Therapeutics, INC 10-Q quarterly reports

TScan Therapeutics reports continued net losses and substantial doubt about its ability to continue as a going concern, with cash reserves expected to fund operations into Q2 2027.

TScan Therapeutics, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, detailing a net loss of $28.7 million and continued investment in its TCR-T therapy pipeline.

TScan Therapeutics reports Q3 2025 results, revealing increased losses, a strategic pivot to heme malignancies, and a 30% workforce reduction to extend cash runway into H2 2027.

TScan Therapeutics reported a widened net loss of $71.1 million for the first half of 2025, driven by increased research and development expenses, as it continues to advance its TCR-T cancer therapies.

TScan Therapeutics reports a net loss of $34.1 million for Q1 2025, with collaboration revenue increasing due to the Amgen agreement.

TScan Therapeutics reports a net loss of $29.9 million for the third quarter of 2024, alongside updates on clinical trials and manufacturing.

TScan Therapeutics reports a net loss of $61.8 million for the first half of 2024, while highlighting progress in clinical trials and platform development.

TScan Therapeutics reports a net loss of $30.1 million for the first quarter of 2024, while highlighting progress in clinical trials and a successful $161.4 million capital raise.